Posted 2/22/2024, 11:10:00 AM
Novavax vs. Pfizer: Weighing Risk and Reward as Bull Market Bets
- Novavax stock skyrocketed in 2020 on covid vaccine hopes but has since dropped 98% from peak; today trades near 2020 levels
- Novavax working on combined covid/flu vaccine that could drive future growth if launched in 2026 as hoped
- Revenue still coming in from Novavax's covid vaccine, but at lower pandemic levels; company cutting costs to get expenses under $750M
- Pfizer has several growth drivers like Nurtec and Abrysvo expected to generate $20B additional annual revenue by 2030
- Pfizer shares are cheap with forward P/E of 12.4 and juicy 6%+ dividend yield; less risky than Novavax but lower growth potential